Home/Executive Briefings/The Buyer’s Case: ROI, Concurrency Pricing, and How to Evaluate a Voice Vendor
Specialty Operations Strategy•June 22, 2026•8 min read

The Buyer’s Case: ROI, Concurrency Pricing, and How to Evaluate a Voice Vendor

Let’s get practical. If you run or buy for a specialty pharmacy and you’ve read this far, the question on your desk is no longer “is this real”...

F
Florent & The SpecialtyRx Operations Research Team
Autonomous Healthcare Infrastructure | San Francisco & New York
The Buyer’s Case: ROI, Concurrency Pricing, and How to Evaluate a Voice Vendor

Let’s get practical. If you run or buy for a specialty pharmacy and you’ve read this far, the question on your desk is no longer “is this real” — it’s “how do I evaluate it, what does it cost, and how do I know it’ll pay off.” So here’s the buyer’s case, straight, with the questions I’d ask if I were sitting in your chair.

Start with the ROI math, not the demo

The voice quality will impress you in a demo. Don’t buy on the demo. Buy on the math, because in specialty pharmacy the math is unusually strong and unusually concrete. Build it from the leaks we’ve documented:

  • Labor. What does it cost you today to staff the call volume? If you’re anywhere near the one-pharmacy example — tens of thousands of calls a month requiring dozens of FTEs — automating the routine majority is a large, direct line item.
  • Recovered refills. Estimate the prescriptions sitting in your blocked-refill queue and your lapsed-refill rate. Those are high-value scripts. Even a modest recovery rate is real revenue, because specialty prescriptions are not cheap.
  • Adherence retention. If 60% of patients drop in the first 30 days, what’s a few points of improvement worth across your book? In specialty, that flows straight to refills and hub-contract performance.
  • Cold-chain saves. With excursions running into five and six figures per shipment, catching even a handful a year can cover the program.
  • Time-to-therapy. Faster onboarding wins and keeps the manufacturer and payer relationships that feed you volume.

Add those up before you ever talk price. In my experience the gap between cost and benefit here isn’t close.

Understand the pricing models

Voice AI is usually priced one of a few ways, and the differences matter for a high-volume operation. Per-minute pricing is common and simple — you pay for talk time, often with telephony costs on top. The thing to watch is that at specialty-pharmacy volumes, per-minute can get unpredictable. I’m a believer in concurrency-based pricing for operations like this: you pay for the number of simultaneous calls you need handled, which makes your cost predictable regardless of volume spikes — and specialty pharmacies have spiky days. Ask whether you can bring your own AI model and telephony keys, too; for some buyers that meaningfully lowers the cost. The right model depends on your call patterns, so map your real volume and concurrency before you sign.

The questions that separate real vendors from answering machines

When you’re in the room with a vendor, these are the ones that matter:

  • Integration. “Show me exactly how you read from and write to my pharmacy management system on a live call.” If they can’t speak fluently about specialty pharmacy platforms and real-time data, walk. This is the whole game.
  • Escalation. “What happens when a patient reports an adverse event, or has a clinical question, or gets upset?” The answer must be clean, conservative escalation to a human. Anyone whose agent tries to play clinician is dangerous.
  • Memory and channel. “Does the agent remember prior calls, and can it move a conversation to SMS?” Continuity is both empathy and efficiency.
  • Compliance and logging. “Show me the audit trail.” In a REMS and accreditation world, documentation isn’t optional.
  • Latency and empathy. Get on a live call yourself. Would it reassure a scared patient? Trust your ears.
  • Proof in specialty. “Where have you done this in specialty pharmacy specifically?” General healthcare or — worse — general industry experience is not the same thing.

Start narrow, prove it, expand

My honest advice: don’t try to automate everything on day one. Pick the workflow with the cleanest ROI and the lowest clinical risk — status and refill calls are usually it — run a real pilot on a slice of your volume, and measure hold time, abandonment, recovered refills, and staff hours freed. Once the number is undeniable, expand into adherence, blocked refills, verification follow-up, and after-hours coverage. This is exactly how the strongest deployments grow: land a beachhead workflow, prove it on the metrics, and let the results pull you into the next one.

The bottom line

Specialty pharmacy is one of the few places where the ROI on voice AI is almost embarrassingly clear, because the work is high-volume, the prescriptions are high-value, and the leaks are everywhere. The buyer’s job isn’t to figure out whether it pays off — it’s to pick a vendor who can actually integrate, escalate safely, and prove it in your environment, then start narrow and let the math do the talking.

Strategic Next Steps

See How Autonomous Multi-Agent Techs Compress Your TTFF

Eliminate 45-minute payer phone holds, automate missing lab provider chases, and protect your biopharma LDD manufacturer panel allocations with 100% pharmacist clinical gating.

Request Architecture WalkthroughExplore More Executive Briefings →

Related Strategic Operational Briefings

May 18, 2026
The LDD Gatekeeper: Why Time-to-First-Fill Is the Only Metric Pharma Cares About (And How Manual Calling Loses Networks)

When biopharma Trade Directors build a five-pharmacy Limited Distribution network, they don't care about how hard your intake team works. They care about Time-to-First-Fill (TTFF) velocity, clean data registries, and zero day-7 abandonment. Here is how manual outbound calling is costing independent and health-system specialty pharmacies their seat at the LDD table.

June 2, 2026
The 45-Minute Hold Problem: How Payer Phone Trees Are Secretly Starving Specialty Pharmacy Margins

Every January during the Great Re-Verification tsunami—and every day thereafter—your highest-paid reimbursement specialists are spending 60% of their payroll hours listening to payer hold music. Let's break down the brutal unit economics of manual Benefits Investigations and how autonomous payer navigation changes the P&L.

June 22, 2026
The $293 Billion Blind Spot: Why Specialty Pharmacy Is Healthcare’s Most Underserved Automation Frontier

Here’s something nobody really cares about and almost nobody knows is there: specialty pharmacy is one of the biggest, fastest-growing, most operationally broken parts of American healthcare...